Culley Brian M
Insider CIK 1310683 · ATMS Chief Executive Officer · ANX CEO and Director, Director · BTX President and CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics, | P Buy | 2026-03-12 | 2026-03-12 | 15,000 | $1.63 | $24.4K | 255,516 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2026-03-05 | 2026-03-06 | 3,250,000 | — | $0 | 3,250,000 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2026-02-11 | 2026-02-13 | 31,250 | — | $0 | 0 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2026-02-11 | 2026-02-13 | 12,869 | $1.80 | $23.2K | 240,516 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2026-02-11 | 2026-02-13 | 31,250 | — | $0 | 253,385 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2025-12-19 | 2025-12-19 | 334 | $1.68 | $561 | 222,135 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award | 2025-12-19 | 2025-12-19 | 8,925 | — | $0 | 222,469 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2025-03-10 | 2025-03-12 | 2,300,000 | — | $0 | 2,300,000 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2025-02-11 | 2025-02-12 | 31,249 | — | $0 | 31,250 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2025-02-11 | 2025-02-12 | 12,547 | $0.65 | $8.2K | 213,544 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2025-02-11 | 2025-02-12 | 31,249 | — | $0 | 226,091 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | P Buy | 2024-11-21 | 2024-11-22 | 40,000 | $0.60 | $24.0K | 194,842 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | P Buy | 2024-05-24 | 2024-05-28 | 10,000 | $1.05 | $10.5K | 154,842 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2024-03-07 | 2024-03-08 | 1,900,000 | — | $0 | 1,900,000 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2024-02-11 | 2024-02-12 | 31,249 | — | $0 | 62,499 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2024-02-11 | 2024-02-12 | 12,806 | $1.08 | $13.8K | 144,842 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2024-02-11 | 2024-02-12 | 31,249 | — | $0 | 157,648 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2023-03-09 | 2023-03-10 | 1,900,000 | — | $0 | 1,900,000 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2023-02-11 | 2023-02-14 | 31,249 | — | $0 | 93,748 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2023-02-11 | 2023-02-14 | 12,744 | $1.35 | $17.2K | 126,399 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2023-02-11 | 2023-02-14 | 31,249 | — | $0 | 139,143 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2022-06-30 | 2022-06-30 | 15,450 | — | $0 | 0 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2022-06-30 | 2022-06-30 | 5,343 | $1.58 | $8.4K | 107,894 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2022-06-30 | 2022-06-30 | 15,450 | — | $0 | 113,237 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2022-03-31 | 2022-04-04 | 15,450 | — | $0 | 15,450 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2022-03-31 | 2022-04-04 | 15,450 | — | $0 | 96,730 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2022-03-31 | 2022-04-04 | 5,343 | $1.54 | $8.2K | 91,387 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | P Buy | 2022-03-31 | 2022-04-04 | 6,400 | $1.53 | $9.8K | 97,787 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | P Buy | 2022-03-25 | 2022-03-28 | 5,250 | $1.38 | $7.2K | 81,280 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2022-03-10 | 2022-03-11 | 300,000 | — | $0 | 300,000 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2022-03-10 | 2022-03-11 | 1,250,000 | — | $0 | 1,250,000 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2022-02-11 | 2022-02-15 | 124,997 | — | $0 | 124,997 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2021-12-31 | 2022-01-03 | 15,450 | — | $0 | 30,900 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2021-12-31 | 2022-01-03 | 5,343 | $2.45 | $13.1K | 76,030 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2021-12-31 | 2022-01-03 | 15,450 | — | $0 | 81,373 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2021-09-30 | 2021-10-12 | 15,450 | — | $0 | 46,350 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2021-09-30 | 2021-10-12 | 15,450 | — | $0 | 71,266 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2021-09-30 | 2021-10-12 | 5,343 | $2.52 | $13.5K | 65,923 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2021-06-30 | 2021-06-30 | 15,450 | — | $0 | 61,800 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2021-06-30 | 2021-06-30 | 15,450 | $2.85 | $44.0K | 61,159 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2021-06-30 | 2021-06-30 | 5,343 | $2.85 | $15.2K | 55,816 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2021-06-28 | 2021-06-30 | 300,000 | — | $0 | 933,300 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | S Sale | 2021-06-28 | 2021-06-30 | 450,000 | $2.87 | $1.29M | 45,709 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2021-06-28 | 2021-06-30 | 300,000 | $0.69 | $207.0K | 495,709 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2021-03-31 | 2021-04-01 | 15,450 | — | $0 | 77,250 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2021-03-31 | 2021-04-01 | 15,450 | $2.35 | $36.3K | 201,052 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2021-03-31 | 2021-04-01 | 5,343 | $2.35 | $12.6K | 195,709 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2021-03-15 | 2021-03-17 | 1,165,100 | — | $0 | 1,165,100 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2020-12-31 | 2020-12-31 | 15,450 | — | $0 | 92,700 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2020-12-31 | 2020-12-31 | 15,450 | $1.76 | $27.2K | 190,945 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2020-12-31 | 2020-12-31 | 5,343 | $1.76 | $9.4K | 185,602 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2020-09-30 | 2020-09-30 | 15,450 | — | $0 | 108,150 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2020-09-30 | 2020-09-30 | 5,343 | $0.94 | $5.0K | 175,495 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2020-09-30 | 2020-09-30 | 15,450 | $0.94 | $14.5K | 180,838 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2020-06-30 | 2020-07-02 | 15,450 | — | $0 | 123,600 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2020-06-30 | 2020-07-02 | 15,450 | $0.87 | $13.4K | 170,731 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2020-06-30 | 2020-07-02 | 5,343 | $0.87 | $4.6K | 165,388 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2020-03-31 | 2020-03-31 | 15,450 | — | $0 | 139,050 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2020-03-31 | 2020-03-31 | 15,450 | $0.83 | $12.8K | 160,624 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2020-03-31 | 2020-03-31 | 5,343 | $0.83 | $4.4K | 155,281 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | A Award deriv | 2020-03-17 | 2020-03-19 | 1,233,300 | — | $0 | 1,233,300 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2019-12-31 | 2019-12-31 | 15,450 | — | $0 | 154,500 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2019-12-31 | 2019-12-31 | 15,450 | — | $0 | 150,517 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2019-12-31 | 2019-12-31 | 5,343 | $0.89 | $4.8K | 145,174 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2019-09-30 | 2019-10-01 | 15,450 | — | $0 | 169,950 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2019-09-30 | 2019-10-01 | 5,343 | $0.98 | $5.2K | 135,067 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2019-09-30 | 2019-10-01 | 15,450 | — | $0 | 140,410 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise deriv | 2019-09-17 | 2019-09-19 | 61,800 | — | $0 | 185,400 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | F Tax w/h | 2019-09-17 | 2019-09-19 | 21,371 | $1.00 | $21.4K | 124,960 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | M Exercise | 2019-09-17 | 2019-09-19 | 61,800 | — | $0 | 146,331 | SEC↗ |
| LCTX Lineage Cell Therapeutics, | P Buy | 2019-08-13 | 2019-08-15 | 10,000 | $1.01 | $10.1K | 84,531 | SEC↗ |
| BTX BIOTIME INC | M Exercise deriv | 2019-01-01 | 2019-01-03 | 100,000 | — | $0 | 0 | SEC↗ |
| BTX BIOTIME INC | F Tax w/h | 2019-01-01 | 2019-01-03 | 40,880 | $0.91 | $37.2K | 59,120 | SEC↗ |
| BTX BIOTIME INC | M Exercise | 2019-01-01 | 2019-01-03 | 100,000 | — | $0 | 100,000 | SEC↗ |
| BTX BIOTIME INC | A Award deriv | 2018-09-17 | 2018-09-19 | 1,500,000 | — | $0 | 1,500,000 | SEC↗ |
| BTX BIOTIME INC | A Award deriv | 2018-09-17 | 2018-09-19 | 100,000 | — | $0 | 100,000 | SEC↗ |
| BTX BIOTIME INC | A Award deriv | 2018-09-17 | 2018-09-19 | 200,000 | — | $0 | 200,000 | SEC↗ |
| ATMS Artemis Therapeutics, Inc. | A Award deriv | 2018-03-15 | 2018-03-19 | 48,528 | — | $0 | 48,528 | SEC↗ |
| ATMS Artemis Therapeutics, Inc. | P Buy deriv | 2017-10-23 | 2017-10-25 | 12,500 | — | $0 | 12,500 | SEC↗ |
| ATMS Artemis Therapeutics, Inc. | P Buy | 2017-10-23 | 2017-10-25 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ATMS Artemis Therapeutics, Inc. | A Award deriv | 2017-08-09 | 2017-09-05 | 242,640 | — | $0 | 242,640 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2017-01-20 | 2017-01-23 | 2,368,194 | — | $0 | 2,368,194 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2016-01-04 | 2016-01-06 | 1,227,100 | — | $0 | 1,227,100 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2015-06-11 | 2015-06-12 | 888,900 | — | $0 | 888,900 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2015-01-02 | 2015-01-02 | 2,100,550 | — | $0 | 2,100,550 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2014-06-19 | 2014-06-20 | 1,114,250 | — | $0 | 1,114,250 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2014-01-02 | 2014-01-03 | 650,300 | — | $0 | 650,300 | SEC↗ |
| MSTX Mast Therapeutics, Inc. | A Award deriv | 2013-06-19 | 2013-06-21 | 907,300 | — | $0 | 907,300 | SEC↗ |
| ANX ADVENTRX PHARMACEUTICALS I | A Award deriv | 2013-01-02 | 2013-01-03 | 138,650 | — | $0 | 138,650 | SEC↗ |
| ANX ADVENTRX PHARMACEUTICALS I | P Buy | 2012-03-14 | 2012-03-15 | 20,500 | $0.59 | $12.1K | 34,500 | SEC↗ |
| ANX ADVENTRX PHARMACEUTICALS I | P Buy | 2012-03-13 | 2012-03-14 | 14,000 | $0.58 | $8.1K | 14,000 | SEC↗ |